Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury

Despite important advances in the treatment of myocardial infarction that have significantly reduced mortality, there is still an unmet need to limit the infarct size after reperfusion injury in order to prevent the onset and severity of heart failure. Multiple cardioprotective maneuvers, therapeuti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Magda C. Díaz-Vesga, Úrsula Zúñiga-Cuevas, Andrés Ramírez-Reyes, Nicolas Herrera-Zelada, Iván Palomo, Roberto Bravo-Sagua, Jaime A. Riquelme
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	cardioprotection aging ischemia/reperfusion injury mitochondria senolytics Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/c5fbf5226e9e4b199430543279c58551
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c5fbf5226e9e4b199430543279c58551
record_format	dspace
spelling	oai:doaj.org-article:c5fbf5226e9e4b199430543279c585512021-11-19T05:27:47ZPotential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury2297-055X10.3389/fcvm.2021.770421https://doaj.org/article/c5fbf5226e9e4b199430543279c585512021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.770421/fullhttps://doaj.org/toc/2297-055XDespite important advances in the treatment of myocardial infarction that have significantly reduced mortality, there is still an unmet need to limit the infarct size after reperfusion injury in order to prevent the onset and severity of heart failure. Multiple cardioprotective maneuvers, therapeutic targets, peptides and drugs have been developed to effectively protect the myocardium from reperfusion-induced cell death in preclinical studies. Nonetheless, the translation of these therapies from laboratory to clinical contexts has been quite challenging. Comorbidities, comedications or inadequate ischemia/reperfusion experimental models are clearly identified variables that need to be accounted for in order to achieve effective cardioprotection studies. The aging heart is characterized by altered proteostasis, DNA instability, epigenetic changes, among others. A vast number of studies has shown that multiple therapeutic strategies, such as ischemic conditioning phenomena and protective drugs are unable to protect the aged heart from myocardial infarction. In this Mini-Review, we will provide an updated state of the art concerning potential new cardioprotective strategies targeting the aging heart.Magda C. Díaz-VesgaMagda C. Díaz-VesgaMagda C. Díaz-VesgaÚrsula Zúñiga-CuevasAndrés Ramírez-ReyesNicolas Herrera-ZeladaIván PalomoIván PalomoRoberto Bravo-SaguaRoberto Bravo-SaguaRoberto Bravo-SaguaJaime A. RiquelmeJaime A. RiquelmeFrontiers Media S.A.articlecardioprotectionagingischemia/reperfusion injurymitochondriasenolyticsDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardioprotection aging ischemia/reperfusion injury mitochondria senolytics Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	cardioprotection aging ischemia/reperfusion injury mitochondria senolytics Diseases of the circulatory (Cardiovascular) system RC666-701 Magda C. Díaz-Vesga Magda C. Díaz-Vesga Magda C. Díaz-Vesga Úrsula Zúñiga-Cuevas Andrés Ramírez-Reyes Nicolas Herrera-Zelada Iván Palomo Iván Palomo Roberto Bravo-Sagua Roberto Bravo-Sagua Roberto Bravo-Sagua Jaime A. Riquelme Jaime A. Riquelme Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury
description	Despite important advances in the treatment of myocardial infarction that have significantly reduced mortality, there is still an unmet need to limit the infarct size after reperfusion injury in order to prevent the onset and severity of heart failure. Multiple cardioprotective maneuvers, therapeutic targets, peptides and drugs have been developed to effectively protect the myocardium from reperfusion-induced cell death in preclinical studies. Nonetheless, the translation of these therapies from laboratory to clinical contexts has been quite challenging. Comorbidities, comedications or inadequate ischemia/reperfusion experimental models are clearly identified variables that need to be accounted for in order to achieve effective cardioprotection studies. The aging heart is characterized by altered proteostasis, DNA instability, epigenetic changes, among others. A vast number of studies has shown that multiple therapeutic strategies, such as ischemic conditioning phenomena and protective drugs are unable to protect the aged heart from myocardial infarction. In this Mini-Review, we will provide an updated state of the art concerning potential new cardioprotective strategies targeting the aging heart.
format	article
author	Magda C. Díaz-Vesga Magda C. Díaz-Vesga Magda C. Díaz-Vesga Úrsula Zúñiga-Cuevas Andrés Ramírez-Reyes Nicolas Herrera-Zelada Iván Palomo Iván Palomo Roberto Bravo-Sagua Roberto Bravo-Sagua Roberto Bravo-Sagua Jaime A. Riquelme Jaime A. Riquelme
author_facet	Magda C. Díaz-Vesga Magda C. Díaz-Vesga Magda C. Díaz-Vesga Úrsula Zúñiga-Cuevas Andrés Ramírez-Reyes Nicolas Herrera-Zelada Iván Palomo Iván Palomo Roberto Bravo-Sagua Roberto Bravo-Sagua Roberto Bravo-Sagua Jaime A. Riquelme Jaime A. Riquelme
author_sort	Magda C. Díaz-Vesga
title	Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury
title_short	Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury
title_full	Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury
title_fullStr	Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury
title_full_unstemmed	Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury
title_sort	potential therapies to protect the aging heart against ischemia/reperfusion injury
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c5fbf5226e9e4b199430543279c58551
work_keys_str_mv	AT magdacdiazvesga potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT magdacdiazvesga potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT magdacdiazvesga potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT ursulazunigacuevas potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT andresramirezreyes potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT nicolasherrerazelada potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT ivanpalomo potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT ivanpalomo potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT robertobravosagua potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT robertobravosagua potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT robertobravosagua potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT jaimeariquelme potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury AT jaimeariquelme potentialtherapiestoprotecttheagingheartagainstischemiareperfusioninjury
_version_	1718420401122443264

Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury

Ejemplares similares